Updates from the American Society of Clinical Oncology (ASCO) Annual Meeting – Solid Tumors
Release date: August 1, 2019
Expiration date: August 1, 2022
BCOP credit must be claimed by: March 5, 2020
ACPE credit must be claimed by: August 28, 2022
HOPA is pleased to present the second of a five-webinar series, which will review key findings from clinical and translational research, and data presented at national oncology meetings. This BCOP webinar will overview key abstracts presented at the American Society of Clinical Oncology 55th Annual Meeting in Chicago, IL May 31 through June 4, 2019. This module will include practice advancing abstracts in sarcoma, breast, head and neck, non-small cell lung, prostate, bladder, and pancreatic cancers. At the end of this presentation, the audience will be able to demonstrate application of emerging ASCO data to real world oncology patients.
- Evaluate findings of American Society of Clinical Oncology (ASCO) research abstracts expected to impact clinical practice and the treatment of oncology patients.
- Identify patient characteristics and pharmacogenomic results necessary for prescribing emerging therapies.
- Differentiate adverse events and supportive care essential in ameliorating cancer complications.
Heidi D. Finnes, PharmD BCOP
Heidi D. Finnes, PharmD, BCOP is the Senior Manager Pharmacy Cancer Center Research at the Mayo Clinic Cancer Center in Rochester, MN. Dr. Finnes obtained her Doctor of Pharmacy degree from Drake University, Des Moines, Iowa in 1998 and her Board Certification in Oncology Pharmacy in 2003. Dr. Finnes is the director of the Mayo Clinic Cancer Center Pharmacy Shared Resource and provides input on oncology clinical trials during protocol development, authors drug templates and offers recommendations for therapy and supportive care. She prepares investigational drug order sets for Epic/Beacon and completes electronic and face to face pharmacy consultations on hematology/oncology patients. Dr. Finnes is the chair of the Alliance for Clinical Trials in Oncology Pharmacy Committee and is active on the Alliance Neuro-Oncology, Cancer Control and Chemoprevention and Experimental Therapeutics Committees. She is a member of the Eastern Oncology Cooperative Group Pharmacy and Melanoma committees. Her research interests include medication therapy management in hematology/oncology patients, pharmacology of experimental therapeutics, and treatment of melanoma. She is also active in the Hematology Oncology Pharmacists Association (HOPA) and served as a HOPA board member at-large, liaison for BCOP committees, chair of the Program Committee and is the current chair of the Time to Talk Immuno-Oncology Task Force.
No financial relationships exist with commercial interests.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-097-H01-P.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by August 28, 2022.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of Board Certified Oncology Pharmacist (BCOP) credit. A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% or greater is achieved. Tests must be completed by March 5, 2020.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and managers for the Hematology/Oncology Pharmacy Association do not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs – all faculty will indicate at the start of their presentations if they or will be referencing unlabeled/unapproved uses of drugs and devices.
HOPA Member – $40
Nonmember Price – $70